McCann Healthcare names four as co-CEOs

Share this article:
McCann Healthcare names four as co-CEOs
McCann Healthcare names four as co-CEOs
McCann Healthcare Worldwide announced a new “Office of the CEO” under which four executives will share leadership responsibility.

The realignment follows the December departure of McCann Healthcare chief Richard Nordstrom, who had held that post since 2005.

The four execs, who will take on responsibility for leading the network in addition to leading their units, are: Marci Piasecki, CEO of Torre Lazur Healthcare Group; Maureen Regan, managing partner of RCW Group; David Backmann, DCFO of McCann Healthcare Worldwide; and John Cahill, president, McCann Healthcare EMEA and Asia Pacific as well as head of med ed.

Cahill, who is based in London, will be first among equals, serving as chairman of the Office of the CEO, with oversight for global operations as well as multinational coordination on behalf of clients, the company said, and will serve as “the single point of contact for the McCann Healthcare Worldwide Network,” though different companies will have different point persons among the four.

McCann Worldgroup chief John Dooner said in a statement: The new structure both recognizes the leadership achievements of the four executives and will help us meet our clients' global needs by fostering increased collaboration between McCann's healthcare companies around the world. We thank Richard for all that he has accomplished and wish him well with his new plans.”

The changes were first reported in the January issue of MM&M.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...